2550 Phase Ib study of abiraterone acetate (AA) plus buparlisib (BKM120) or BEZ235 in patients (pts) with castration-resistant prostate cancer (CRPC). (September 2015) - Chi, K.; Castellano, D.; De Bono, J.; Gravis, G.; Dirix, L.; Machiels, J.P.; Mita, A.; Mellado Gonzalez, B.; Massard, C.; Trandafir, L.; Dey, D.; Csonka, D.; et al.